Showing results (1081-1090 of 1,611) with videos related to

Sort By:
Pageof 162
JAMA Oncology|April 7, 2017
Clinical Characterization of the Pheochromocytoma and Paraganglioma Susceptibility Genes SDHA, TMEM127, MAX, and SDHAF2 for Gene-Informed PreventionBirke Bausch, Francesca Schiavi, Ying Ni, et al.
JAMA Oncology|July 12, 2019
Effect of Pembrolizumab After Stereotactic Body Radiotherapy vs Pembrolizumab Alone on Tumor Response in Patients With Advanced Non-Small Cell Lung Cancer: Results of the PEMBRO-RT Phase 2 Randomized Clinical TrialWillemijn S M E Theelen, Heike M U Peulen, Ferry Lalezari, et al.
JAMA Oncology|January 24, 2017
Comparison of Prevalence and Types of Mutations in Lung Cancers Among Black and White PopulationsJoshua D Campbell, Christopher Lathan, Lynette Sholl, et al.
JAMA Oncology|January 24, 2017
Topical Imiquimod Plus Nab-paclitaxel for Breast Cancer Cutaneous Metastases: A Phase 2 Clinical TrialLupe G Salazar, Hailing Lu, Jessica L Reichow, et al.
JAMA Oncology|March 10, 2017
Adjuvant Treatment for High-Risk Clear Cell Renal Cancer: Updated Results of a High-Risk Subset of the ASSURE Randomized TrialNaomi B Haas, Judith Manola, Janice P Dutcher, et al.
JAMA Oncology|March 18, 2021
Effect of Second-generation vs Third-generation Chemotherapy Regimens With Thoracic Radiotherapy on Unresectable Stage III Non-Small-Cell Lung Cancer: 10-Year Follow-up of a WJTOG0105 Phase 3 Randomized Clinical TrialYoshitaka Zenke, Masahiro Tsuboi, Yasutaka Chiba, et al.
JAMA Oncology|February 10, 2022
Efficacy and Safety of Autologous Dendritic Cell-Based Immunotherapy, Docetaxel, and Prednisone vs Placebo in Patients With Metastatic Castration-Resistant Prostate Cancer: The VIABLE Phase 3 Randomized Clinical TrialNicholas J Vogelzang, Tomasz M Beer, Winald Gerritsen, et al.
JAMA Oncology|July 28, 2022
Evaluation of Treatment With Talazoparib and Avelumab in Patients With Recurrent Mismatch Repair Proficient Endometrial CancerPanagiotis A Konstantinopoulos, Allison A Gockley, Niya Xiong, et al.
JAMA Oncology|July 21, 2022
Log-Rank Test vs MaxCombo and Difference in Restricted Mean Survival Time Tests for Comparing Survival Under Nonproportional Hazards in Immuno-oncology Trials: A Systematic Review and Meta-analysisPralay Mukhopadhyay, Jiabu Ye, Keaven M Anderson, et al.
JAMA Oncology|April 14, 2022
Quality-of-Life Outcomes and Toxic Effects Among Patients With Cancers of the Uterus Treated With Stereotactic Pelvic Adjuvant Radiation Therapy: The SPARTACUS Phase 1/2 Nonrandomized Controlled TrialEric Leung, Adam P Gladwish, Melanie Davidson, et al.
Pageof 162